Some of the best teen - and pre-teen - players from the Peninsula and other parts of the state will gather at Centre Court Racquet Club this weekend for the Peninsula Tennis Patrons Association Thanksgiving Classic junior tournament. Participants with symptomatic TEPS had significantly more respiratory exacerbations than those with asymptomatic TEPS (0.23 vs 0.08 exacerbations per person-year, respectively rate ratio, 2.38, P < .001).Ĭonclusions and Relevance Participants with symptomatic TEPS did not have accelerated rates of decline in FEV 1 or increased incidence of COPD vs those with asymptomatic TEPS, but participants with symptomatic TEPS did experience significantly more respiratory exacerbations over a median follow-up of 5.8 years.E-Pilot Evening Edition Home Page Close Menu The cumulative incidence of COPD was 33.0% among participants with symptomatic TEPS vs 31.6% among those with asymptomatic TEPS (hazard ratio, 1.05 ). At a median follow-up of 5.76 years, the decline in FEV 1 was −31.3 mL/y for participants with symptomatic TEPS vs −38.8 mL/y for those with asymptomatic TEPS (between-group difference, −7.5 mL/y ). ![]() Results Of 1397 study participants, 226 had symptomatic TEPS (mean age, 60.1 years 134 were women ) and 269 had asymptomatic TEPS (mean age, 63.1 years 134 were women ). Secondary outcomes included development of COPD defined by spirometry, respiratory symptoms, rates of respiratory exacerbations, and progression of computed tomographic–defined airway wall thickening or emphysema. Main Outcomes and Measures The primary outcome was assessment for accelerated decline in lung function (FEV 1) in participants with symptomatic TEPS vs asymptomatic TEPS. Patient-reported respiratory symptoms and exacerbations were assessed every 4 months via phone calls. Participants with asymptomatic TEPS had normal spirometry and COPD Assessment Test scores of less than 10. Participants with symptomatic TEPS had normal spirometry (postbronchodilator ratio of forced expiratory volume in the first second to forced vital capacity >0.70) and COPD Assessment Test scores of 10 or greater. Respiratory symptoms were assessed with the COPD Assessment Test (range, 0 to 40 higher scores indicate more severe symptoms). Participants in SPIROMICS II had 1 additional in-person visit 5 to 7 years after enrollment in SPIROMICS I. Participants were enrolled in SPIROMICS I and II from November 10, 2010, through July 31, 2015, and followed up through July 31, 2021.Įxposures Participants in SPIROMICS I underwent spirometry, 6-minute walk distance testing, assessment of respiratory symptoms, and computed tomography of the chest at yearly visits for 3 to 4 years. Objective To define the natural history of persons with tobacco exposure and preserved spirometry (TEPS) and symptoms (symptomatic TEPS).ĭesign, Setting, and Participants SPIROMICS II was an extension of SPIROMICS I, a multicenter study of persons aged 40 to 80 years who smoked cigarettes (>20 pack-years) with or without COPD and controls without tobacco exposure or airflow obstruction. These individuals are typically excluded from chronic obstructive pulmonary disease (COPD) trials and lack evidence-based therapies. Importance People who smoked cigarettes may experience respiratory symptoms without spirometric airflow obstruction. Bradley Drummond, MD, MHS 4 MeiLan K. Han, MD, MS 16 Nadia N. Hansel, MD, MPH 19 Kinsey Helton, MS 3 Eric A. Hoffman, PhD 6,15,20 Robert J. Kaner, MD 21 Richard E. Kanner, MD 22 Jerry A. Krishnan, MD 23 Stephen C. Lazarus, MD 1,24 Fernando J. Martinez, MD, MS 21 Jill Ohar, MD 25 Victor E. Ortega, MD, PhD 26 Robert Paine III, MD 22 Stephen P. Peters, MD, PhD 25 Joseph M. Reinhardt, PhD 6 Stephen Rennard, MD 27 Benjamin M. Smith, MD, MSc 8,28 Donald P. Tashkin, MD 7 David Couper, PhD 3 Christopher B. Cooper, MD, PhD 7,29 Prescott G. Woodruff, MD, MPH 1,24 Graham Barr, MD, PhD 8,9 Eugene R. Bleecker, MD 10,11 John Boscardin, PhD 12 Russell P. Bowler, MD, PhD 13 Russell G. Buhr, MD, PhD 7 Gerard J. Criner, MD 14 Alejandro P. Comellas, MD 15 Jeffrey L. Curtis, MD 16,17 Mark Dransfield, MD 18 Claire M. Doerschuk, MD 4 Brett A. Dolezal, PhD 7 M. William McKleroy, MD 1,2 Tracie Shing, PhD 3 Wayne H. Anderson, MEd, PhD 4 et al Mehrdad Arjomandi, MD 1,5 Hira Anees Awan, MB 6 Igor Barjaktarevic, MD, PhD 7 R.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |